ASCO Annual Meeting

Patients Should Ask Their Providers About Clinical Trial Results

July 7th 2021, 6:00pm


Results demonstrating the efficacy of Bavencio highlight the importance of incorporating recent clinical trial successes into the treatment conversation.

New Potential Immunotherapy Treatment Options in Advanced Esophageal Squamous Cell Carcinoma

June 28th 2021, 3:00pm


Opdivo was the first PD-1 inhibitor to show durable responses in patients with esophageal squamous cell carcinoma.

Novel 4-Drug Combo Significantly Improves Treatment Responses in Group of Patients with Breast Cancer

June 15th 2021, 6:00pm


Treatment with pyrotinib and the chemotherapies trastuzumab, docetaxel and carboplatin significantly improved response rates over the triplet chemotherapy regimen alone in the neoadjuvant treatment of patients with HER2-positive breast cancer.

Trodelvy Associated with Better Benefits Than Chemo in Metastatic Triple-Negative Breast Cancer, Regardless of Agent

June 9th 2021, 3:00pm


The data, according to the study’s lead author, confirm that Trodelvy should be considered a new standard of care in patients with metastatic triple-negative breast cancer.

Patients with Early Triple-Negative Breast Cancer May Benefit from Imfinzi-Neoadjuvant Chemo Combo

June 8th 2021, 5:00pm


Patients with early triple-negative breast cancer receiving Imfinzi in addition to neoadjuvant chemotherapy saw increased survival rates and complete responses to treatment.

Novel Therapy Appears Safe in Certain Patients with Prostate Cancer

June 7th 2021, 6:30pm


The treatment was also associated with antitumor activity in patients with metastatic castration-resistant prostate cancer.

Novel Therapy Shows Promise in Group of Patients with Metastatic Colon Cancer

June 7th 2021, 2:30pm


Responses to the study drug, according to one of the study’s authors, appeared far superior than what would have been expected with other treatments in patients with HER2-expressing metastatic colorectal cancer.

Imfinzi May Contribute to Long-Term Survival Improvements in Unresectable Non-Small Cell Lung Cancer

June 7th 2021, 1:00pm


The long-term follow-up data, according to one of the study’s authors from the Sarah Cannon Cancer Institute, demonstrate “a new benchmark for the standard of care” in the treatment of patients with unresectable stage 3 non-small cell lung cancer.

Aumolertinib Improves Survival in Advanced Non-Small Cell Lung Cancer

June 7th 2021, 12:00pm


Treatment with aumolertinib was associated with prolonged survival in patients with advanced non-small cell lung cancer.

Abecma Continues to Improve Survival in Heavily Pretreated Patients With Multiple Myeloma

June 6th 2021, 8:00pm


After long-term follow-up, the CAR-T cell therapy still boosted survival outcomes in patients with relapsed/refractory multiple myeloma, regardless of the number of prior lines of therapy received.